Back to top

Piper Sandler Reaffirms Their Buy Rating on Aclaris Therapeutics (ACRS)

In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Aclaris Therapeutics, with a price target of $11.00. According...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Aclaris Therapeutics, Inc. (ACRS)